What is influenza?

Influenza is a highly contagious respiratory illness caused by influenza virus. There are two main types of human influenza viruses: A and B. There are also many sub-types and strains. Flu can occur throughout the year but is most common in autumn and winter. In most flu seasons there is more than one strain circulating in the community.

What are the symptoms of flu?

People with flu often experience some or all the following symptoms:

  • Fever and chills
  • Cough, sore throat and runny or stuffy nose
  • Muscle aches, joint pains, headaches and fatigue (feeling very tired)

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

More articles like this

2022 interim results: Financial & corporate highlights

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma plc completes in-licence of Melioidosis vaccine candidate

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF, a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that further to the Option Agreement announced in December 2021, Poolbeg has signed an exclusive Licence Agreement with University College

Poolbeg Pharma to attend HC Wainwright Global Investment Conference

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has announced that the Company’s Chairman, Cathal Friel, will be attending the HC Wainwright Global Investment Conference, which is taking place

Poolbeg Pharma well capitalised as they enter exciting phase

London-listed Poolbeg Pharma “is entering a very exciting” phase, its chief executive said on Monday, after the company received human trial approval for its influenza drug in the UK in July. Unaudited interim results published by the company

Poolbeg Pharma entering a very exciting phase in development

Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, today announced its unaudited interim results for the six months to 30 June 2022. Financial & Operational Highlights • Well capitalised with

Why is artificial intelligence important for drug discovery?

AI Magazine explores the importance of artificial intelligence (AI) as the healthcare industry continues to digitise and utilise tech for drug discovery Recently MarketsandMarkets released an exclusive report on artificial intelligence (AI) in drug discovery and found that the

Drug discovery is about to get faster. Thank AI

Last month, Alphabet’s artificial intelligence subsidiary, DeepMind, stunned the world of science by presenting something truly spectacular: a snapshot of nearly every existing protein on Earth — 200 million of them. This machine-learning feat could speed the creation

Poolbeg Pharma gets go ahead for severe influenza drug trial

Poolbeg Pharma has received ethics and competent authority approval to commence its lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment

Regulatory approval gives green light for LPS trial to proceed

Poolbeg Pharma has received ethics and competent authority approval to commence its Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain agnostic, small molecule immunomodulator which aims to address the unmet medical need for a treatment

Poolbeg Pharma appoints Singer Capital Markets as Joint Broker

Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has appointed Singer Capital Markets as Joint Broker with immediate effect. finnCap Ltd will continue to act as Nominated Adviser and

POLB 001 Human Challenge trial ready to commence

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma gets human trial approval for flu drug

London-listed Poolbeg Pharma has received regulatory approval in the UK to proceed with human clinical trials of its influenza drug POLB 001. The company, which spun out from Dublin-listed pharmaceutical services business Open Orphan last year, said the

How AI can improve the drug discovery process

AI is an advanced form of machine learning that can rapidly analyse very large datasets, highlight non-intuitive trends resulting in the identification of novel disease targets and associated drugs. AI can tilt the odds of drug development by

Poolbeg Pharma’s POLB001 human challenge clinical trial to commence

Poolbeg Pharma plc (LON:POLB’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has received ethics and competent authority approval to commence its Lipopolysaccharide (LPS) human challenge clinical trial for POLB 001, a strain

No more posts to show